PBYI
Puma Biotechnology, Inc.
Biotechnology · Healthcare · United States
8.71
close · 2026-08-13
value
73
cheaper than peers73
quality
70
stronger fundamentals70
ranked against
Biotechnology (commercial)
value
quality
101 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 2.00× | 96 |
| EV to EBITDA | 8.31× | 73 |
| price to book | 3.21× | 70 |
| forward P/E | 24.89× | 34 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | 21.6% | 83 |
| operating margin | -8.5% | 67 |
| debt to equity | 12.4% | 63 |
| revenue growth | -2.6% | 28 |
4 of 4 measures available
Facts
| market cap | $450M |
| free cash flow | $44.1M |
| employees | 179 |
| first trade | 2012-04-24 |
| next earnings | 2026-08-06 |
| fundamentals updated | 2026-08-07 |